Page 15 - PRESENTATION

OS and PFS benefit with avelumab 1L maintenance was observed

irrespective of best response to 1L chemotherapy

Complete response (N=179)

Median OS (95% CI), months Median PFS (95% CI), months
Avelumab + BSC NE (20.8, NE) Avelumab + BSC 7.4 (4.3, 16.5)
100 100
BSC alone NE (18.5, NE) BSC alone 3.8 (2.1, 5.6)
90 90
HR 0.81 (95% CI, 0.47, 1.38) HR 0.65 (95% CI, 0.45, 0.96)
80 80
70 70
60 60
OS, % 50 PFS, % 50

40 40
30 30
20 20
10 10
0 0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38
Months Months
No. at risk No. at risk
Avelumab +BSC 90 90 85 79 70 63 53 41 3 5 3 3 1 3 2 4 2 1 8 2 14 13 10 7 3 0 Avelumab +BSC 90 61 49 42 30 26 20 18 17 10 8 7 6 4 3 1 0
BSC 89 89 86 79 69 57 51 46 14 12 3 2 1 0 BSC 89 50 38 27 21 19 15 15 13 12 7 7 5 2 1 0
8 1 6 2

•OS and PFS were measured post randomization (after chemotherapy); CR (ie, no evidence of disease at baseline), PR, and SD at baseline was based on either BICR or investigator assessment up to protocol amendment 3, or
investigator assessment only from protocol amendment 3 (19 Dec 2016) onward

Grivas P, ESMO 2020